Gurugram, India – February 5, 2025 – Jagsonpal Pharmaceuticals Limited has announced a key leadership change in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The Board of Directors has approved the appointment of Mr. Sachin Jain as the new Chief Financial Officer (CFO) of the company. Following this appointment, the company has updated its list of Key Managerial Personnel (KMPs) authorized to determine the materiality of events and disclosures to stock exchanges.
The company has formally notified both the BSE and National Stock Exchange of India (NSE) regarding this update.
Strategic Implications
This leadership restructuring aligns with Jagsonpal Pharmaceuticals’ broader efforts to enhance corporate governance and compliance. The inclusion of the CFO in regulatory disclosure decision-making is expected to streamline financial reporting processes and reinforce transparency with investors.
